Pharmacokinetics of Optivate®, a high-purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A

Haemophilia

Volumn 17, Issue 2, 2011, Pages 185-190

  Dmoszynska, A ^a   Hellmann, A ^b   Baglin, T ^c   O'shaugnessy, D ^d   Trelinski, J ^e   Kuliczkowski, K ^f   Kloczko, J ^g   Hay, C ^h   Zawilska, K ⁱ   Makris, M ^j   Shaikh Zaidi, R ^k   Gascoigne, E ^k   Dash, C ^k  

^a Medical University of Lublin Klinika Hematoonkologii i Transplantacji Szpiku AM w Lublinie   (Poland)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^e MEDICAL UNIVERSITY OF LODZ   (Poland)

^f WROCLAW MEDICAL UNIVERSITY   (Poland)

^g MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^h MANCHESTER ROYAL INFIRMARY   (United Kingdom)

ⁱ POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^j ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^k BIO PRODUCTS LABORATORY   (United Kingdom)

more..

Author keywords

Factor VIII; Haemophilia A; Pharmacokinetics; Plasma concentrations; Recovery

Indexed keywords

8Y; CZYNNIK; RECOMBINANT BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CHILD; DISEASE SEVERITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; HEMOPHILIA A; HUMAN; MAJOR CLINICAL STUDY; MEAN RESIDENCE TIME; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; CHILD; FACTOR VIII; HEMOPHILIA A; HUMANS; METABOLIC CLEARANCE RATE; MIDDLE AGED; PROSPECTIVE STUDIES; VON WILLEBRAND FACTOR; YOUNG ADULT;

EID: 79951788029     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02414.x     Document Type: Article

References (25)

1. Rizza CR, Fletcher ML, Kernoff PB. Confirmation of viral safety of dry heated Factor VIII concentrate (8Y) prepared by Bio Products Laboratory (BPL): a report on behalf of UK Haemophilia Centre Directors. Br J Haematol 1993; 84: 269-72.
2. Colvin BT, Rizza RC, Hill GH et al. Effect of dry-heating of coagulation factor concentrates at 80 degrees C for 72 hours on transmission of non-A, non-B hepatitis Study Group of the UK Haemophilia Centre Directors on Surveillance of Virus Transmission by Concentrates. Lancet 1988; 2: 814-6.
3. Kreil TR, Berting A, Kistner O, Kindermann J. West nile virus and the safety of plasma derivatives: verification of high safety margins, and the validity of predictions based on model virus data. Transfusion 2003; 43: 1023-8.
4. Remington KM, Trejo SR, Buczynski G et al. Inactivation of west nile virus, vaccine virus and viral surrogates for relevant and emergent viral pathogens in plasma-derived products. Vox Sang 2004; 87: 10-8.
5. Yee TT, Lee CA, Pasi KJ. Life-threatening human parvovirus B19 infection in immunocompetent haemophilia. Lancet 1995; 345: 794-5.
6. Roberts PL, Dunkerley C. Effect of manufacturing process parameter on virus inactivation by solvent-detergent treatment in a high-purity factor IX concentrate. Vox Sang 2003; 84: 170-5.
7. Yee TT, Williams MD, Hill FG, Lee CA, Pasi KJ. Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a single intermediate purity Factor VIII product. Thromb Haemost 1997; 78: 1027-9.
8. Brown SA, Dasani H, Collins PW. Long-term follow up of patients treated with intermediate FVIII concentrate BPL 8Y. Haemophilia 1998; 4: 89-93.
9. Pasi KJ, Hill FG. Safety trial of heated factor VIII concentrate (8Y). Arch Dis Child 1989; 64: 1463-7.
10. ®, a high purity factor IX concentrate. Pharmacoepidemiol Drug Saf 2004; 13: 187-95.
11. Notes for guidance to assess efficacy and safety of human plasma derived factor VIII: C and factor VIII:C products in clinical studies in haemophiliacs before and after authorisation (CPMP/BPWG/198/95 rev.1)
12. Dmoszynska A, K.Kuliczkowski AK, Hellmann A et al. Clinical assessment of Optivate, a new high-purity concentrate of factor VIII (FVIII) with von Willebrand factor (VWF), in the management of patients with haemophilia A. July 2010 submitted for publication.
13. Scientific and standardization committee communication. The design and analysis of pharmacokinetic studies of coagulation factors, 2001.
14. Morfini M. Pharmacokinetics of factor VIII and factor IX. Haemophilia 2003; 9: 94-100.
15. Lee M, Morfini M, Schulman S, Ingerslev J. The design and analysis of pharmacokinetic studies of coagulation factors. Factor VIII/IX SSC-ISTH recommendations at .
16. Messori A, Longo G, Matucci M, Morfini M, Ferrini PLR. Clinical Pharmacokinetics of Factor VIII in patients with classic haemophilia. Clin Pharmacokinet 1987; 13: 365-80.
17. Cinotti S, Longo G, Messori A et al. Reproducibility of one-stage, two-stage and chromogenic assays of factor VIII activity: a multi-centre study. Thromb Res 1991; 61: 385-93.
18. Rosen S. A rebuttal: issues with the assay of Factor VIII activity in plasma and Factor VIII concentrates. Thromb Haemost 2001; 86: 1132-3.
19. Lee C, Barrowcliffe T, Bray G et al. Pharmacokinetics in vivo comparison using 1-stage and chromogenic substrate assays with two formulations of Hemofil-M. Thromb Haemost 1996; 76: 950-6.
20. Morfini M, Lee M, Messori A. The design and analysis of half-life and recovery studies for factor VIII and factor IX. Thromb Haemost 1991; 66: 384-6.
21. Bjorkman S Carsson M, Berntorp E, Stenberg P. Pharmacokinetics of factor VIII in humans obtaining clinically relevant data from comparative studies. Clin Pharmacokinet 1992; 22: 385-95.
22. Messori A, Morfini M, Blomback M et al. Pharmacokinetics of two pasteurised factor VIII concentrates by different and multicenter assays of FVIII activity. Thromb Res 1992; 65: 699-708.
23. Bjorkman S, Berntorp E. Pharmacokinetics of coagulation factors, clinical relevance for patients with haemophilia. Clin Pharmacokinet 2001; 40: 815-32.
24. ® S/D) in previously treated patients with severe hemophilia A: results of a prospective, multicenter, open-label phase III study. Acta Haematol 2008; 119: 89-97.
25. Bjorkman S, Folkesson A, Berntorp E. In vivo recovery of factor VIII and Factor IX: intra- and inter-individual variance in a clinical setting. Haemophilia 2007; 13: 2-8.